HB0017

DRUG3 trials

Sponsors

Huabo Biopharm Co., Ltd.

Conditions

Healthy SubjectsPlaque PsoriasisPsoriasis (PsO)

Phase 1

A Study of Injection HB0017 in Adult Healthy Volunteers

CompletedNCT04505033

Huabo Biopharm Co., Ltd.Healthy Subjects

Start: 2020-10-02End: 2021-02-01Updated: 2021-07-28

Phase 2

A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

CompletedNCT05531682

Huabo Biopharm Co., Ltd.Plaque Psoriasis

Start: 2022-10-25End: 2024-01-04Updated: 2024-06-21

A Phase 2 Study of HB0017 in Psoriasis Patients

RecruitingNCT06592274

Huabo Biopharm Co., Ltd.Psoriasis (PsO)

Start: 2024-09-30End: 2026-01-30Target: 200Updated: 2025-09-15

Related Papers

Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis

British Journal of Dermatology2023-09-037 citations